RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES
... past decade. During the first few years after the PSA test was put into widespread use, the rate seemed to increase dramatically. This was likely not due to more men actually having the disease, however. With a better screening method in place . more men with prostate cancer were actually being diag ...
... past decade. During the first few years after the PSA test was put into widespread use, the rate seemed to increase dramatically. This was likely not due to more men actually having the disease, however. With a better screening method in place . more men with prostate cancer were actually being diag ...
Incidental prostate cancer detected in cystoprostatectomy
... be placed in a close follow up with PSA test as they may need adjuvant therapy in the future. ...
... be placed in a close follow up with PSA test as they may need adjuvant therapy in the future. ...
Screening for prostate cancer: an updated Cochrane systematic
... ‘Within each country, men were assigned to either the screening group or the control group . . . on the basis of random number generators’. Method of concealment was not described in the publication. It is also unclear whether method of concealment differed among study sites given that different ran ...
... ‘Within each country, men were assigned to either the screening group or the control group . . . on the basis of random number generators’. Method of concealment was not described in the publication. It is also unclear whether method of concealment differed among study sites given that different ran ...
Take the next step to know if you are at increased risk for cancer
... If you answered yes to any of these questions, you could be at increased risk for developing colon, breast, ovarian, pancreatic, prostate or uterine cancer. To know for sure, further assessment is necessary. Experts at the cancer genetics ...
... If you answered yes to any of these questions, you could be at increased risk for developing colon, breast, ovarian, pancreatic, prostate or uterine cancer. To know for sure, further assessment is necessary. Experts at the cancer genetics ...
APGI 2016 - Australian Pancreatic Cancer Genome Initiative
... Rationale for screening 10Y between the initial mutation and the birth of first pancreatic cancer cell and another 6 years for the development of the clone with metastatic potential Broad window of opportunity for early ...
... Rationale for screening 10Y between the initial mutation and the birth of first pancreatic cancer cell and another 6 years for the development of the clone with metastatic potential Broad window of opportunity for early ...
Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen
... Complete blood counts were obtained before each docetaxel dose. Physical examination, assessment of adverse events, serum PSA, and serum biochemistry were examined every 4 weeks. Serum calcium was checked weekly for the first 4 weeks. If serum calcium remained within the normal range during the firs ...
... Complete blood counts were obtained before each docetaxel dose. Physical examination, assessment of adverse events, serum PSA, and serum biochemistry were examined every 4 weeks. Serum calcium was checked weekly for the first 4 weeks. If serum calcium remained within the normal range during the firs ...
Recent Findings on Diet, Nutrition, Physical Activity and Cancer: the
... Dose-response meta-analysis of body fatness and prostate cancer Waist to hip ratio ...
... Dose-response meta-analysis of body fatness and prostate cancer Waist to hip ratio ...
epidemiology of prostate cancer - Direct-MS
... across 11 screening studies, and the negative predictive value was 91%.46 At the higher cutoff point of 10 ng/mL, the positive predictive value improved to 47%, but this came at the expense of a reduction in the sensitivity of screening. An abnormal DRE finding increases the likelihood that prostate ...
... across 11 screening studies, and the negative predictive value was 91%.46 At the higher cutoff point of 10 ng/mL, the positive predictive value improved to 47%, but this came at the expense of a reduction in the sensitivity of screening. An abnormal DRE finding increases the likelihood that prostate ...
Sequencing Systemic Therapies in Metastatic Castration
... for the treatment of mCRPC patients with bone metastases in November 2010. The role of denosumab in preventing bone metastasis or death in nonmetastatic CRPC has been examined. In a study protocol that randomized 1,432 men with CRPC at high risk for bone metastases (PSA ≥ 8 μg/L, PSA doubling time ≤ ...
... for the treatment of mCRPC patients with bone metastases in November 2010. The role of denosumab in preventing bone metastasis or death in nonmetastatic CRPC has been examined. In a study protocol that randomized 1,432 men with CRPC at high risk for bone metastases (PSA ≥ 8 μg/L, PSA doubling time ≤ ...
Slide 1 - Marianna Lordos
... million cancer deaths in EU 25 (estimated figures for 2006) - Every day, more than 6000 Europeans are diagnosed with cancer and 3000 die from their disease. - The number of Europeans with cancer will increase dramatically by 2015 largely due to the ageing population ...
... million cancer deaths in EU 25 (estimated figures for 2006) - Every day, more than 6000 Europeans are diagnosed with cancer and 3000 die from their disease. - The number of Europeans with cancer will increase dramatically by 2015 largely due to the ageing population ...
Clinical Phenotypes of Castration
... state that has therapeutic implications. In the TAX-327 and the goal of therapy in this setting is to delay the onset (Docetaxel Plus Prednisone or Mitoxantrone Plus Predof symptomatic metastases while also extending life. Thus, nisone for Advanced Prostate Cancer) study, in which nonmetastatic or l ...
... state that has therapeutic implications. In the TAX-327 and the goal of therapy in this setting is to delay the onset (Docetaxel Plus Prednisone or Mitoxantrone Plus Predof symptomatic metastases while also extending life. Thus, nisone for Advanced Prostate Cancer) study, in which nonmetastatic or l ...
British journalist takes first prize in prestigious cancer
... Two British journalists win joint first prize in prestigious cancer journalism award 15 June 2009 – Margaret McCartney and Linda Geddes are joint winners of the European School of Oncology’s Best Cancer Reporter Award (BCRA) for 2009. The Award was established by the European School of Oncology (ESO ...
... Two British journalists win joint first prize in prestigious cancer journalism award 15 June 2009 – Margaret McCartney and Linda Geddes are joint winners of the European School of Oncology’s Best Cancer Reporter Award (BCRA) for 2009. The Award was established by the European School of Oncology (ESO ...
Fremskrivning av kreftinsidens
... So what is the difference between a traditional cancer register and a ...
... So what is the difference between a traditional cancer register and a ...
PROSTATE CANCER – WellbeingNET Facilitator Guide
... and the group throughout the awareness session. A positive environment will maximise both discussion and learning. Below are some suggested open-ended questions that may help you to begin a more open discussion around prostate cancer: 1. Was there any information in the video that surprised you? Was ...
... and the group throughout the awareness session. A positive environment will maximise both discussion and learning. Below are some suggested open-ended questions that may help you to begin a more open discussion around prostate cancer: 1. Was there any information in the video that surprised you? Was ...
030717 The Influence of Finasteride on the Development of Prostate
... rectal examination, no clinically significant coexisting conditions, and an American Urological Association symptom score4 of less than 20 were recruited. The study was approved by institutional review boards at all sites. After the men had given written informed consent, blood was drawn to determin ...
... rectal examination, no clinically significant coexisting conditions, and an American Urological Association symptom score4 of less than 20 were recruited. The study was approved by institutional review boards at all sites. After the men had given written informed consent, blood was drawn to determin ...
Contribution of Androgen Deprivation Therapy to
... castrate men with nonmetastatic prostate cancer (16). Our results raise the possibility that a bisphosphonate dose/schedule sufficient to increase bone mineral density in castrate men may also be adequate to prevent skeletal-related events in castrate men with bone metastases. The study design was c ...
... castrate men with nonmetastatic prostate cancer (16). Our results raise the possibility that a bisphosphonate dose/schedule sufficient to increase bone mineral density in castrate men may also be adequate to prevent skeletal-related events in castrate men with bone metastases. The study design was c ...
Castration-Resistant Prostate Cancer
... that patients who are positive for this marker be treated with a different agent or agents. This work has recently been validated by Scher et al, who showed that patients with AR-V7 had superior outcomes when treated with taxane chemotherapy.2 The clear implication of this study is that measurement ...
... that patients who are positive for this marker be treated with a different agent or agents. This work has recently been validated by Scher et al, who showed that patients with AR-V7 had superior outcomes when treated with taxane chemotherapy.2 The clear implication of this study is that measurement ...
Prostate Cancer Clinical Trials of the Southwest Oncology Group
... judgement has been influenced by the fact that these patients tend to be older and have comorbid conditions and, most importantly, that no effective systemic therapy has been found. From a clinical trials perspective, progress in treating this disease has been hindered by the paucity of active agent ...
... judgement has been influenced by the fact that these patients tend to be older and have comorbid conditions and, most importantly, that no effective systemic therapy has been found. From a clinical trials perspective, progress in treating this disease has been hindered by the paucity of active agent ...
SEOM Clinical guidelines for the treatment of metastatic prostate
... guidelines state that its use should no longer be regarded as investigational (Level of evidence: 2), IADT can be used in patients relapsing after radiotherapy and with clear response after the induction period [8]. Level of evidence: 1b. In metastatic patients, a trial of IADT showed worse survival ...
... guidelines state that its use should no longer be regarded as investigational (Level of evidence: 2), IADT can be used in patients relapsing after radiotherapy and with clear response after the induction period [8]. Level of evidence: 1b. In metastatic patients, a trial of IADT showed worse survival ...